Q-omics provides the consensus-scored GAPDHP1 profile across patient tissues and cancer cell-line models. GAPDHP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GAPDHP1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GAPDHP1 RNA expression shows 13,600 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LIHC, KIRC, and LUAD as cancer lineages where GAPDHP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP1 survival associations across molecular data types. GAPDHP1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP1 RNA expression–survival associations across cancer types. High GAPDHP1 expression shows unfavorable associations in LIHC, MESO, KIRP, LAML and LUAD, but favorable associations in READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GAPDHP1 RNA expression.
This table summarizes GAPDHP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP1 shows higher tumor expression in KIRC, LUAD, COAD, LUSC, LIHC and UCEC. The KIRC box plot shows higher GAPDHP1 RNA expression in tumor versus normal tissue (log2 FC = +2.013, t-test p < 0.001).
This table shows molecular features associated with GAPDHP1 in patient tissues and cancer cell lines. In patient samples, GAPDHP1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
